KR102200892B1 - 펠루비프로펜의 신규 염, 이의 제조방법 및 이를 포함하는 약학적 조성물 - Google Patents

펠루비프로펜의 신규 염, 이의 제조방법 및 이를 포함하는 약학적 조성물 Download PDF

Info

Publication number
KR102200892B1
KR102200892B1 KR1020190055671A KR20190055671A KR102200892B1 KR 102200892 B1 KR102200892 B1 KR 102200892B1 KR 1020190055671 A KR1020190055671 A KR 1020190055671A KR 20190055671 A KR20190055671 A KR 20190055671A KR 102200892 B1 KR102200892 B1 KR 102200892B1
Authority
KR
South Korea
Prior art keywords
felubiprofen
tromethamine
present
tromethamine salt
pelubiprofen
Prior art date
Application number
KR1020190055671A
Other languages
English (en)
Korean (ko)
Other versions
KR20200131382A (ko
Inventor
김철우
박상욱
신상윤
조민용
이원일
손세일
Original Assignee
대원제약주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 대원제약주식회사 filed Critical 대원제약주식회사
Priority to KR1020190055671A priority Critical patent/KR102200892B1/ko
Priority to CN202080030464.0A priority patent/CN113891873B/zh
Priority to PCT/KR2020/006219 priority patent/WO2020231146A1/fr
Publication of KR20200131382A publication Critical patent/KR20200131382A/ko
Application granted granted Critical
Publication of KR102200892B1 publication Critical patent/KR102200892B1/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/86—Unsaturated compounds containing keto groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/80—Unsaturated compounds containing keto groups containing rings other than six-membered aromatic rings
    • C07C59/82—Unsaturated compounds containing keto groups containing rings other than six-membered aromatic rings the keto group being part of a ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020190055671A 2019-05-13 2019-05-13 펠루비프로펜의 신규 염, 이의 제조방법 및 이를 포함하는 약학적 조성물 KR102200892B1 (ko)

Priority Applications (3)

Application Number Priority Date Filing Date Title
KR1020190055671A KR102200892B1 (ko) 2019-05-13 2019-05-13 펠루비프로펜의 신규 염, 이의 제조방법 및 이를 포함하는 약학적 조성물
CN202080030464.0A CN113891873B (zh) 2019-05-13 2020-05-12 新型培比洛芬盐、其制备方法及包含其的药物组合物
PCT/KR2020/006219 WO2020231146A1 (fr) 2019-05-13 2020-05-12 Nouveau sel de pélubiprofène, son procédé de préparation et composition pharmaceutique le comprenant

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020190055671A KR102200892B1 (ko) 2019-05-13 2019-05-13 펠루비프로펜의 신규 염, 이의 제조방법 및 이를 포함하는 약학적 조성물

Publications (2)

Publication Number Publication Date
KR20200131382A KR20200131382A (ko) 2020-11-24
KR102200892B1 true KR102200892B1 (ko) 2021-01-12

Family

ID=73289029

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020190055671A KR102200892B1 (ko) 2019-05-13 2019-05-13 펠루비프로펜의 신규 염, 이의 제조방법 및 이를 포함하는 약학적 조성물

Country Status (3)

Country Link
KR (1) KR102200892B1 (fr)
CN (1) CN113891873B (fr)
WO (1) WO2020231146A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102372908B1 (ko) 2021-09-27 2022-03-10 유니셀랩 주식회사 새로운 펠루비프로펜/만델산 공결정

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023080299A1 (fr) * 2021-11-08 2023-05-11 일동제약(주) Nouveau sel d'un dérivé de l'acide phénylpropionique, son procédé de production et composition pharmaceutique le contenant
WO2023182869A1 (fr) * 2022-03-25 2023-09-28 Ildong Pharmaceutical Co., Ltd. Nouveau sel de composé agoniste du récepteur glp-1, son procédé de préparation et composition pharmaceutique le comprenant

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6038323A (ja) * 1983-08-10 1985-02-27 Sankyo Co Ltd 眼科用消炎剤
WO2001037838A1 (fr) * 1999-11-24 2001-05-31 Wakamoto Pharmaceutical Co., Ltd. Preparation aqueuse ophtalmique
ES2343168T3 (es) * 2001-05-31 2010-07-26 Hisamitsu Pharmaceutical Co., Inc. Parches de absorcion por via percutanea.
EP2098500A1 (fr) * 2008-03-07 2009-09-09 Laboratorios Del. Dr. Esteve, S.A. Sels de Ménantine et co-inhibiteur et leur forme cristalline pour le traitement de la douleur
KR100922519B1 (ko) 2008-11-12 2009-10-20 대원제약주식회사 펠루비프로펜을 함유하는 용출률 및 안정성이 개선된 경구투여용 약제학적 제제
CN102093234B (zh) * 2009-11-26 2014-06-18 福州乾正药业有限公司 一种二元酯酸的氨丁三醇盐化合物及其制备方法和药物应用
CN102743341B (zh) * 2012-07-28 2014-02-26 西安德天药业股份有限公司 右旋酮洛芬氨丁三醇缓释微粒及其制备方法和缓释制剂
HU231045B1 (en) * 2015-12-01 2020-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Zrt Novel process for the preparation of carboprost tromethamine
JP1637767S (fr) 2018-12-03 2019-07-29

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102372908B1 (ko) 2021-09-27 2022-03-10 유니셀랩 주식회사 새로운 펠루비프로펜/만델산 공결정

Also Published As

Publication number Publication date
KR20200131382A (ko) 2020-11-24
CN113891873A (zh) 2022-01-04
WO2020231146A1 (fr) 2020-11-19
CN113891873B (zh) 2024-03-15

Similar Documents

Publication Publication Date Title
KR102200892B1 (ko) 펠루비프로펜의 신규 염, 이의 제조방법 및 이를 포함하는 약학적 조성물
CZ286621B6 (cs) Tromethaminová sůl (+)-(S)-2-(3-benzoylfenyl)propionové kyseliny, způsob její výroby a farmaceutický prostředek s jejím obsahem
US20080234323A1 (en) Amorphous and Three Crystalline Forms of Rimonabant Hydrochloride
JP2001508400A (ja) アセチルコリンエステラーゼ阻害剤および鎮痛剤としてのイサチン誘導体
JP6203170B2 (ja) アゴメラチンの新しい結晶形ｖｉｉ、その調製方法及び使用並びにこれを含有する医薬組成物
KR20170061616A (ko) 피마살탄의 신규 염
RU2290924C2 (ru) Фармацевтическая композиция, включающая кристаллический полугидрат метансульфоната сибутрамина
US11236041B2 (en) Type-G crystal form of fenolamine, preparation method, composition and use thereof
US20230174546A1 (en) Crystalline form a of glp-1 receptor agonist and preparation method therefor
KR102235994B1 (ko) 환상 아민 유도체의 결정 및 그 의약 용도
US20110269838A1 (en) Novel processes and pure polymorphs
WO2009075504A2 (fr) Forme cristalline du p-toluènesulfonate de bépostatine, son procédé de préparation et composition pharmaceutique la contenant
CN112851500B (zh) S-洛索洛芬衍生物及其制备方法、药物组合物和用途
KR102170422B1 (ko) 토파시티닙의 신규 염, 이의 제조방법 및 이를 포함하는 약학 조성물
HRP20000037A2 (en) New salts with beneficial organoleptic properties
JPS61122275A (ja) 新規ヒダントイン誘導体及び該化合物を含有する医薬組成物
JPH09124644A (ja) テラゾシン結晶性ポリモルフ及びその製薬組成物
US8754129B2 (en) Crystalline vorinostat form VI
KR102552315B1 (ko) 펠루비프로펜 신규 염을 주성분으로 하며 위장장애 부작용이 저감된 약학적 조성물
CN114349665B (zh) 二甲双胍焦谷氨酸晶体及其制备方法与应用
JP2711939B2 (ja) ６−クロロ−５−フルオロ−３−（２−テノイル）−２−オキシンドール−１−カルボキサミドのリジン塩
US4156009A (en) Diazepine derivatives
CN113402390B (zh) 一种阿司匹林药物共晶体及其制备方法和应用
JPH02237928A (ja) 置換ベンズアミドより成る胃の自動運動性増進用薬剤
KR100632470B1 (ko) 결정성 시부트라민 캄실레이트염과 이의 제조방법

Legal Events

Date Code Title Description
E701 Decision to grant or registration of patent right
GRNT Written decision to grant